Sign in
GHRS Stock Price, Chart, Stats & News
GH Research PLC
Save
GH Research PLC (GHRS) does not currently pay a dividend.
1.63B
Market cap
–
Current P/E
–
Forward P/E
GHRS chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -16.74% |
ROE | -16.30% |
D/E | 0.00x |
Interest coverage ratio | -131.04x |
GHRS valuation
P/E | – |
P/S | – |
P/B | 2.92x |
P/CF | -18.44x |
P/FCF | -18.39x |
P/OCF | -18.44x |
PEG | 2.08x |
EV multiple | -21.04x |
About
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients.
Similar securities
Based on sector and market capitalization
Report issue